1-2 of 2
Jean-Louis Legoux
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses

Subject Area:
Endocrinology , Neurology and Neuroscience
Louis de Mestier, Thomas Walter, Hedia Brixi, Camille Evrard, Jean-Louis Legoux, Paul de Boissieu, Olivia Hentic, Jérôme Cros, Pascal Hammel, David Tougeron, Catherine Lombard-Bohas, Vinciane Rebours, Philippe Ruszniewski, Guillaume Cadiot
Journal: Neuroendocrinology
Neuroendocrinology (2019) 108 (4): 343–353.
https://doi.org/10.1159/000498887
Published Online: 13 February 2019
View article titled, Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses
Open the PDF for Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses in another window
Journal Articles

Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE)

Subject Area:
Endocrinology , Neurology and Neuroscience
Guillaume Roquin, Eric Baudin, Catherine Lombard-Bohas, Guillaume Cadiot, Sophie Dominguez, Rosine Guimbaud, Patricia Niccoli, Jean-Louis Legoux, Emmanuel Mitry, Vincent Rohmer, Philippe Ruszniewski, Thomas Walter, Michel Ducreux, Anne Couvelard, Jean-Yves Scoazec, Aline Ramond-Roquin, François-Xavier Caroli-Bosc, Olivia Hentic
Journal: Neuroendocrinology
Neuroendocrinology (2017) 106 (1): 38–46.
https://doi.org/10.1159/000457955
Published Online: 03 February 2017
View article titled, Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE)
Open the PDF for Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE) in another window